Latest Licensing Agreements News

Pro Medicus Limited reports a record-breaking year with $520 million in new contracts and a surge in cloud adoption, setting the stage for continued growth. The company also advances its AI and cardiology offerings, reinforcing its market position.

Lithium Universe Limited has acquired exclusive global rights to Macquarie University's innovative electrochemical silver extraction technology, promising a cleaner, more efficient way to recycle silver from solar panels while preserving valuable silicon wafers.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

Livium Ltd and Mineral Resources Ltd have formalised a 50 – 50 joint venture to commercialise the innovative LieNA® lithium processing technology, aiming to license it globally despite current market headwinds.

X2M Connect Limited has completed a $309,000 entitlement offer by issuing 23.76 million new shares and options, while a substantial shortfall of nearly 127 million shares remains available for placement.

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

Weebit Nano reports solid progress in Q4 FY25 with key technology milestones and its first product design license, backed by a strong cash position.

NoviqTech launches Quantum Intelligence Pty Ltd, introducing hybrid quantum computing solutions with a $1.25 million placement to accelerate growth and product rollout.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

Uscom Limited reported a significant revenue decline in Q4 2025 amid global market instability but is focusing on cost management and strategic partnerships to position for recovery.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.